TMED3

Across TCGA pan-cancer cohorts, TMED3 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated TMED3 data layer compared with 27 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher TMED3 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated TMED3 expression acts as an unfavorable survival marker.

HNSC, CCRCC, and LUAD are the cancer types where TMED3 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Tertile	IV	0.568	0.912	.001	62	view →
CCRCC	OS	Median	All	0.660	1.000	.009	10	view →
LUAD	DFS	Tertile	II,III,IV	0.296	0.684	.026	8	view →
PDAC	OS	Median	III,IV	0.248	0.576	.025	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

TMED3–HNSC (OS)

Open the HNSC breakdown →